Brexpiprazole in patients with schizophrenia: Overview of short-and long-Term phase 3 controlled studies

Acta Neuropsychiatrica

Volumn 29, Issue 5, 2017, Pages 278-290

  Marder, Stephen R ^a   Hakala, Mika Juhani ^b   Josiassen, Mette Krog ^b   Zhang, Peter ^c   Ouyang, John ^c   Weiller, Emmanuelle ^b   Weiss, Catherine ^c   Hobart, Mary ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b H LUNDBECK A S   (Denmark)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

efficacy; maintenance; PANSS; safety; schizophrenia

Indexed keywords

BREXPIPRAZOLE; PLACEBO; QUETIAPINE; NEUROLEPTIC AGENT; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ADVERSE EVENT; AKATHISIA; BODY WEIGHT GAIN; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INCIDENCE; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREVALENCE; PROGRAM EVALUATION; RELAPSE; RESTLESSNESS; REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; SCHIZOPHRENIA; SHORT COURSE THERAPY; SOMNOLENCE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT PLANNING; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINOLONES; SCHIZOPHRENIA; THIOPHENES; TREATMENT OUTCOME;

EID: 84995687172     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1017/neu.2016.57     Document Type: Review

References (52)

1. SINGH S, LOKE YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials 2012;13:138.
2. FRIEDMAN LM, FURBERG CD, DEMETS DL. Fundamentals of clinical trials, 4th edn. New York: Springer, 2010.
3. ANNEMANS L, KUBIN M. Real-life data: A growing need. International Society for Pharmacoeconomics and Outcomes in Research (ISPOR) 2007;13:8-12.
4. The Association of the British Pharmaceutical Industry (ABPI). The vision for real world data-harnessing the opportunities in the UK, White paper, London: ABPI, 2011, pp. 1-23.
5. MCGRATH J, SAHA S, CHANT D, WELHAM J. Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67-76.
6. MESSIAS EL, CHEN CY, EATON WW. Epidemiology of schizophrenia: review of findings and myths. Psychiatr Clin North Am 2007;30:323-338.
7. BOBES J, GARCIA-PORTILLA MP, BASCARAN MT, SAIZ PA, BOUSONO M. Quality of life in schizophrenic patients. Dialogues Clin Neurosci 2007;9:215-226.
8. LIEBERMAN JA, PERKINS D, BELGER A et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001;50:884-897.
9. VOLAVKA J, CITROME L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 2009;10:1917-1928.
10. BROWNE S, CLARKE M, GERVIN M, WADDINGTON JL, LARKIN C, OCALLAGHAN E. Determinants of quality of life at first presentation with schizophrenia. Br J Psychiatry 2000;176:173-176.
11. HAYHURST KP, MASSIE JA, DUNN G, LEWIS SW, DRAKE RJ. Validity of subjective versus objective quality of life assessment in people with schizophrenia. BMC Psychiatry 2014;14:365.
12. CORRELL CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010;25(Suppl. 2):S12-S21.
13. OLIVARES JM, SERMON J, HEMELS M, SCHREINER A. Definitions and drivers of relapse in patients with schizophrenia: A systematic literature review. Ann Gen Psychiatry 2013;12:32.
14. American Psychiatric Association (APA). Practice guidelines for the treatment of patients with schizophrenia, 2nd edn, vol. 2. Arlington, VA: APA, 2010, p. 1-184.
15. TAJIMA-POZO K, DE CASTRO OLLER MJ, LEWCZUK A, MONTANES-RADA F. Understanding the direct and indirect costs of patients with schizophrenia. F1000Res 2015;4:182.
16. YOUNG SL, TAYLOR M, LAWRIE SM. First do no harm. A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol 2015;29:353-362.
17. BARNES TR, Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011;25:567-620.
18. MAEDA K, LERDRUP L, SUGINO H et al. Brexpiprazole II: Antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014;350:605-614.
19. MAEDA K, SUGINO H, AKAZAWA H et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonindopamine activity modulator. J Pharmacol Exp Ther 2014;350:589-604.
20. FLEISCHHACKER WW. Aripiprazole. Expert Opin Pharmacother 2005;6:2091-2101.
21. KANE JM, SKUBAN A, OUYANG J et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixeddose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 2015;164:127-135.
22. CORRELL CU, SKUBAN A, OUYANG J et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: A 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015;172:870-880.
23. FLEISCHHACKER W, HOBART M, OUYANG J et al. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: A randomised, double-blind, placebo-controlled study. Int J Neuropharmacol 2016, in press, doi: 10.1093/ijnp/pyw076.
24. KAY SR, FISZBEIN A, OPLER LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
25. GUY W. ECDEU assessment manual for psychopharmacology: US Department of Health, Education and Welfare Publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health, 1976.
26. MOROSINI PL, MAGLIANO L, BRAMBILLA L, UGOLINI S, PIOLI R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000;101:323-329.
27. AUQUIER P, SIMEONI MC, SAPIN C et al. Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: The S-QoL. Schizophr Res 2003;63:137-149.
28. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders, Text Revision (DSMIV-TR), 4th edn. Arlington, VA: APA, 2000.
29. SIMPSON GM, ANGUS JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19.
30. BARNES TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
31. POSNER K, BROWN GK, STANLEY B et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-1277.
32. LEUCHT S, KANE JM, ETSCHEL E, KISSLING W, HAMANN J, ENGEL RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006;31:2318-2325.
33. RABINOWITZ J, BERARDO CG, BUGARSKI-KIROLA D, MARDER S. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcarerelated quality of life and family burden: A CATIE analysis. Schizophr Res 2013;150:339-342.
34. NASRALLAH H, MOROSINI P, GAGNON DD. Reliability, validity and ability to detect change of the Personal and Social Performance Scale in patients with stable schizophrenia. Psychiatry Res 2008;161:213-224.
35. AMRI I, MILLER A, TOUMI M. Minimum clinically important difference in the global assessment functioning in patients with schizophrenia. Value Health 2014;17:A765-A766.
36. THWIN SS, HERMES E, LEW R et al. Assessment of the minimum clinically important difference in quality of life in schizophrenia measured by the Quality of Well-Being Scale and diseasespecific measures. Psychiatry Res 2013;209:291-296.
37. KANE JM, FLEISCHHACKER WW, HANSEN L, PERLIS R, PIKALOV A III, ASSUNCAO-TALBOTT S. Akathisia: An updated review focusing on second-generation antipsychotics. J Clin Psychiatry 2009;70:627-643.
38. RUMMEL-KLUGE C, KOMOSSA K, SCHWARZ S et al. Second-generation antipsychotic drugs and extrapyramidal side effects: A systematic review and meta-Analysis of headto-head comparisons. Schizophr Bull 2012;38:167-177.
39. KANE JM, ZUKIN S, WANG Y et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol 2015;35:367-373.
40. CALABRESE JR, KECK PE JR., STARACE A et al. Efficacy and safety of low-And high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: A double-blind, placebo-controlled study. J Clin Psychiatry 2015;76: 284-292.
41. MARDER SR, MCQUADE RD, STOCK E et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-Term, placebo-controlled trials. Schizophr Res 2003;61:123-136.
42. DURGAM S, STARACE A, LI D et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: A phase II trial. Bipolar Disord 2015;17: 63-75.
43. CITROME L, OTA A, NAGAMIZU K, PERRY P, WEILLER E, BAKER RA. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. Int Clin Psychopharmacol 2016;31:192-201.
44. LAOUTIDIS ZG, LUCKHAUS C. 5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: A systematic review and meta-Analysis. Int J Neuropsychopharmacol 2014;17:823-832.
45. ADHAM N, GYERTYAN I, KISS B. Cariprazine demonstrates greater potency than aripiprazole in animal models of psychosis, cognitive impairment, and negative symptoms. European Neuropsychopharmacology 2014;24(Suppl. 2): S109-S804.
46. LEUCHT S, CIPRIANI A, SPINELI L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-Treatments meta-Analysis. Lancet 2013;382: 951-962.
47. DE HERT M, DETRAUX J, VAN WINKEL R, YU W, CORRELL CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011;8:114-126.
48. DE HERT M, YU W, DETRAUX J, SWEERS K, VAN WINKEL R, CORRELL CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: A systematic review and exploratory meta-Analysis. CNS Drugs 2012;26:733-759.
49. MELTZER HY, CUCCHIARO J, SILVA R et al. Lurasidone in the treatment of schizophrenia: A randomized, double-blind, placebo-And olanzapine-controlled study. Am J Psychiatry 2011;168:957-967.
50. STAHL SM, CUCCHIARO J, SIMONELLI D, HSU J, PIKALOV A, LOEBEL A. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: A 6-month, open-label, extension study. J Clin Psychiatry 2013;74:507-515.
51. CONLEY RR, MAHMOUD R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-774.
52. RUMMEL-KLUGE C, KOMOSSA K, SCHWARZ S et al. Head-To-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-Analysis. Schizophr Res 2010;123:225-233.